Stepan’s 1Q25 results reflected broad-based operational improvements and earnings growth across its core businesses. Net sales rose 8% y/y to $593.3M, driven by a 4% increase in global sales volumes and a 7% increase in selling prices, partially offset by a 3% negative impact from foreign currency translation. These gains were partially offset by softer demand in commodity Consumer Products markets. Improved product and customer mix, along with the passthrough of higher raw material costs, contributed to a 12% increase in average selling prices. Notably, specialty products delivered strong results with net sales increasing 11% y/y due to higher selling prices and margin recovery within the Medium Chain Triglycerides (MCT) product line. Looking ahead, management expects continued growth across key strategic end markets and volume acceleration supported by the newly operational Pasadena, Texas alkoxylation facility, which is anticipated to drive additional supply chain savings and support margin expansion through the balance of 2025.